Every 8-K that DNA X (SONM) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow SONM and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full SONM filings page.
DNA X, Inc. (SONM) reports that a Nasdaq Hearings Panel has determined the company has regained compliance with Nasdaq Listing Rule 5550(b)(1), which requires companies on the Nasdaq Capital Market to maintain at least $2.5 million of stockholders’ equity. Under a prior Panel decision, the company’s securities remain subject to delisting if it fails to comply with all Nasdaq listing rules through November 18, 2026. In addition, under Nasdaq Listing Rule 5815(d)(4)(B), the company will be under a mandatory panel monitor until August 28, 2027. If during that one-year monitoring period Nasdaq staff again finds the company below the stockholders’ equity requirement, staff must issue a delisting determination without allowing a compliance plan or cure period, although the company could request a new hearing and its securities may then be delisted.
DNA X, Inc. (SONM) disclosed that on August 21, 2026, the compensation committee of its board of directors approved a cash award program ("Substitute Cash Grants") for all board members, including Chief Executive Officer Mike Mulica. These cash awards are being made in lieu of restricted stock units (RSUs) under the company’s 2019 Equity Incentive Plan because no shares remain available under that plan.
The Substitute Cash Grants are structured to closely replicate the company’s existing non-employee director RSU compensation policy. Each grant will equal the fair market value of the company’s common stock underlying the Phantom RSUs at the time of the applicable vesting event and will be paid in cash at that vesting event rather than in stock.
DNA X, Inc. reported that on August 7, 2026 it sold and issued the remaining 416,667 shares of Series B Preferred Stock under its Purchase Agreement, receiving $2.5 million in cash. The company presented a pro forma view showing estimated ending stockholders’ equity of $5,840,000 as of that date.
Based on this pro forma equity, the company believes it now exceeds the $2.5 million stockholders’ equity requirement for continued listing on The Nasdaq Capital Market under Listing Rule 5550(b)(1) and is awaiting Nasdaq’s formal determination. Management notes the pro forma figures are unaudited, based on current estimates and assumptions, and for illustrative purposes only.
DNA X, Inc. amended a prior report to detail a preferred stock financing that improves its stockholders’ equity and supports continued listing on the Nasdaq Capital Market.
On July 8, 2026 the company sold 929,864 shares of Series B Preferred Stock for $2.5 million in cash and cancellation of $3.1 million of a convertible note, and expects to issue another 416,667 shares by August 14, 2026. A pro forma table shows stockholders’ equity moving from deficits in Q1 2026 and estimated Q2 2026 to an estimated $3.8 million as of July 9, 2026, above Nasdaq’s $2.5 million equity requirement, while the company awaits Nasdaq’s formal compliance determination.
DNA X, Inc. entered into a private placement with major holder DNA Holdings Venture to issue 1,346,531 shares of non-voting Series B Convertible Preferred Stock at $6.00 per share, for an aggregate $8.1 million consisting of $5.0 million in cash and cancellation of $3.1 million of note principal.
The Series B Preferred will automatically convert into Common Stock after stockholder approval at an initial conversion price equal to the $6.00 stated value, with customary anti-dilution adjustments and registration rights for resale of the underlying shares. The preferred stock has no general voting rights, a 1x liquidation preference and is not redeemable.
DNA Holdings receives preemptive rights to participate in future financings for 12 months, capped at 50% of each deal. At closing, DNA X also expects to enter a consulting agreement with DNA Holdings, Scott Walker and Brock Pierce, providing 2,494,000 shares of Common Stock as equity consideration, subject to stockholder approval.
DNA X, Inc. terminated its financing arrangements with Chardan Capital Markets LLC that had allowed Chardan to purchase up to $500 million of DNA X common stock. These arrangements consisted of a ChEF Purchase Agreement and a related Registration Rights Agreement.
The termination was effected by letter agreement and became effective as of 5:00 p.m. New York City time on May 28, 2026. These agreements had previously given Chardan the ability to buy shares over time and required DNA X to register those shares for resale.
DNA X, Inc. entered a Securities Purchase Agreement with DNA Holdings Venture, Inc. and issued a secured convertible promissory note with principal of $3,052,787.68. The company received $1,800,000.00 in cash and cancelled a prior $1,200,000.00 note plus accrued interest.
The new note matures on December 31, 2026, bears 10% annual interest, and is convertible into common stock at $6.00 per share, subject to stockholder approval and adjustment. Proceeds must be used for working capital, excluding repayment of most debt, equity redemptions, or litigation settlements.
The company also amended a Membership Interest Purchase Agreement to terminate a put option and secured the note with a first-priority lien on its ownership interests in DNA X, LLC. Separately, Nasdaq staff issued a delisting determination after the company reported a stockholders’ deficit of $983,000 versus the $2,500,000 stockholders’ equity requirement. DNA X plans to request a hearing, but there is no assurance it will regain or maintain Nasdaq listing compliance.
DNA X, Inc. reported first-quarter 2026 results that reflect its exit from the legacy mobile device business and pivot to an AI-driven crypto trading platform. The company sold its mobile device design and manufacturing assets to NEXA for $15 million, less a $1.5 million working capital adjustment, generating $6.3 million in net income from the sale.
From continuing operations, DNA X recorded a $3.9 million net loss as it invested in the DNA X AI trading platform, while revenue from phones and hotspots is now reported in discontinued operations. Cash was $1.2 million at March 31, 2026, and the company agreed to raise an additional $1.8 million through new debt to fund working capital and support growth of the AI and crypto trading business.
DNA X, Inc. filed an 8-K announcing that its Audit Committee dismissed Baker Tilly US, LLP as independent registered public accounting firm and approved the engagement of TAAD LLP for the fiscal year ending December 31, 2026.
Baker Tilly’s reports on the 2024 and 2025 financial statements were generally unqualified but the 2025 report included a statement raising substantial doubt about the company’s ability to continue as a going concern. The company also disclosed a continuing material weakness in internal control over financial reporting related to insufficient technical accounting expertise for complex, non-routine transactions, which has not yet been remediated.
The company reported no disagreements with Baker Tilly on accounting, disclosure, or audit scope, and no other reportable events beyond the previously disclosed material weakness. Baker Tilly provided a letter to the SEC agreeing with the company’s description of these matters, filed as Exhibit 16.1.
DNA X, Inc. reported full-year 2025 results showing a net loss of $20.7 million, improved from $33.6 million in 2024, with no revenue from continuing operations. Continuing-operations net loss was $8.0 million, driven mainly by $5.4 million in general and administrative expenses and higher interest and other expenses.
The company completed its strategic pivot from mobile devices to cryptocurrency trading. It acquired the DNA X trading platform in December 2025 and sold its mobile device design and manufacturing business to NEXA for $15 million in January 2026. Most proceeds repaid debt and other obligations, with remaining cash earmarked to support the trading business.
As of December 31, 2025, cash and cash equivalents were $1.3 million, total assets $43.9 million, total liabilities $50.6 million, and stockholders’ deficit $8.0 million. The company rebranded to DNA X, Inc., operates a DeFi-based automated trading platform, and experienced leadership changes, including the CEO’s resignation and appointment of its Executive Chairman as acting CEO.
DNA X, Inc. filed an amended current report to clarify the accounting treatment of its acquisition of DNA X LLC. The company had purchased 100% of the membership interests in DNA X LLC for 223,201 shares of its common stock, representing 19.99% of its outstanding common shares at issuance.
After a detailed financial analysis, DNA X determined that this transaction does not involve a “significant amount of assets” for purposes of Item 2.01 of the Exchange Act rules. As a result, the company concluded the transaction did not trigger Item 2.01 disclosure and will not provide the financial statements or pro forma financial information that were referenced in its earlier report.
DNA X, Inc. appointed executive chairman Mike Mulica as acting chief executive officer and principal executive officer effective February 9, 2026. Mulica’s annual base salary was increased to $450,000, and he received 50,000 restricted stock units vesting monthly over one year, along with up to 12 months of COBRA premium reimbursement if his employment terminates and he elects continuation coverage.
The company also amended Chief Financial Officer Clay Crolius’s employment agreement, confirming that the previously announced asset sale completed on January 23, 2026 is a triggering event under his contract. Crolius was granted 35,000 RSUs vesting monthly over one year and may receive up to six months of COBRA premium reimbursement following a qualifying termination.
DNA X, Inc. reported major leadership changes, with chief executive officer Peter Liu resigning as CEO and director on January 30, 2026, and chief commercial officer Charles Becher resigning effective January 29, 2026. Both entered separation and release agreements that include general releases of claims against the company.
Liu will receive a total cash severance of $855,000, now split into two payments, while Becher will receive a $250,000 lump-sum severance. The board appointed Scott Walker, a beneficial owner of DNA Holdings Venture, Inc., as a director under DNA Holdings’ right to designate a board member tied to prior investment agreements.
DNA X, Inc. (formerly Sonim Technologies) has completed the previously announced sale of substantially all assets of its enterprise 5G solutions business to Pace Car Acquisition LLC. After purchase price adjustments, the company reports approximately $6.2 million of Post-Closing Cash, including repayment of about $5.4 million of indebtedness.
The company amended the asset purchase agreement to replace an escrow with a $1.5 million holdback, which the buyer can use for purchase price adjustments and certain indemnities, with any remaining amount expected to be released nine months after closing. DNA X prepaid two promissory notes to Streeterville Capital at 110% of their outstanding balances, terminating those obligations.
Following the transaction, DNA X changed its corporate name and plans to focus on developing and commercializing an on-chain trading protocol for automated decentralized exchange strategies, and expects to change its trading symbol to DNAX. Based on the asset sale, the company believes it has regained compliance with Nasdaq’s $2.5 million stockholders’ equity requirement but notes there is no assurance Nasdaq will concur and that continued listing will be monitored.
Sonim Technologies entered a financing and acquisition transaction with DNA Holdings. The company issued a $1,200,000 unsecured convertible promissory note bearing 10% annual interest and maturing on December 15, 2026, receiving cash proceeds of $1,200,000. Beginning six months after issuance, the note is convertible at an initial price of $5.50 per share, with anti-dilution and “full ratchet” protections, subject to a floor of $1.10 and required stockholder approvals for certain adjustments.
Concurrently, Sonim acquired 100% of the membership interests in DNA X LLC, a DeFi trading protocol business, by issuing 223,201 shares of common stock, described as 19.99% of the company’s outstanding common stock at issuance. DNA Holdings agreed to a voting arrangement supporting a previously signed asset purchase agreement and gained rights to designate one officer and one board nominee while holding at least 5% of Sonim’s stock. DNA Holdings also received a put option allowing it, under specified trading volume or revenue thresholds for DNA X before June 30, 2026, to exchange its Sonim shares back for the DNA X interests.
The note and related agreements include covenants limiting additional debt, liens, equity repurchases, other debt repayments, and dividends while the note is outstanding. Separately, Sonim entered an exchange agreement with Streeterville Capital that reduced the outstanding balance of a prior note to approximately $2.3 million and issued additional shares, contributing to a total of 1,488,465 common shares outstanding after the reported transactions.
Sonim Technologies, Inc. reports an amendment to its previously announced asset purchase agreement under which Pace Car Acquisition LLC agreed to buy substantially all assets related to Sonim’s enterprise 5G solutions business for $15,000,000 in cash, subject to working capital, indebtedness, and transaction expense adjustments. The amendment removes all provisions related to a proposed reverse merger transaction, which is no longer relevant to closing this asset sale. It also adds a requirement that if the adjusted Closing Purchase Price would be less than zero, Sonim must pay enough of its accounts payable so that the Closing Purchase Price remains positive, and it adds Sonim Technologies Germany GmbH to the list of acquired subsidiaries.
Sonim Technologies announced it has regained compliance with Nasdaq’s minimum bid price requirement. Nasdaq determined that from October 27, 2025 to November 11, 2025, the closing bid price of SONM common stock was at $1.00 per share or greater, satisfying Listing Rule 5550(a)(2). Nasdaq marked the matter as closed.
Sonim Technologies filed an 8-K stating it issued a press release announcing financial results for the fiscal quarter ended September 30, 2025. The press release is furnished as Exhibit 99.1.
Sonim Technologies announced a reverse stock split of its common stock at a 1-for-18 ratio, approved by stockholders and the Board. The split will be effected by a certificate of amendment and will become effective at 12:01 a.m. Eastern Time on October 27, 2025.
Every eighteen shares will combine into one share with no change to par value. No fractional shares will be issued; holders entitled to a fraction will receive cash in lieu based on the October 20, 2025 closing price (as adjusted). The stock will begin trading on a split-adjusted basis on October 27, 2025 under the existing ticker SONM. The new CUSIP will be 83548F 408.
Sonim Technologies reported multiple corporate actions. Nasdaq granted an extension through December 31, 2025 to regain compliance with Listing Rule 5550(b)(1), which requires $2.5 million in stockholders’ equity. The company submitted a compliance plan and noted that failure to meet requirements could lead to delisting.
The board set a 1-for-18 reverse stock split expected to take effect at 12:01 a.m. ET on October 27, 2025, aimed at meeting the minimum bid price. Stockholders approved increasing authorized common shares from 100,000,000 to 1,000,000,000, which was filed and became effective on October 16, 2025. They also approved the reverse split authority, while a proposed 1,000,000‑share increase to the 2019 Equity Incentive Plan was not approved. A quorum was reached with 12,056,361 shares (about 67.8%) represented.
The board appointed Michael Mulica as Executive Chairman effective October 16, 2025, with a $300,000 base salary, an annual $250,000 RSU grant vesting quarterly over two years, and a $500,000 RSU award tied to a specified asset purchase, with cash substitutes possible if plan share availability is insufficient.
Sonim Technologies entered a committed equity facility with Chardan Capital Markets that allows Sonim, at its option, to sell newly issued common shares for up to $500,000,000 in aggregate gross purchase price, subject to limits including an exchange cap of 2,066,747 shares, equal to 19.99% of shares outstanding before the agreement. Sales will be priced off the stock’s volume weighted average price with a fixed 3.5% discount and can occur over a 36‑month period after the resale registration statement becomes effective.
Chardan’s beneficial ownership is capped at 4.99% of outstanding shares, and per‑day purchases are further limited by dollar, trading‑volume and contract thresholds. Sonim plans to use at least 33% of any proceeds to prepay a $2,755,000 promissory note to Streeterville Capital, with the balance intended for operations, working capital and general corporate purposes.
Sonim Technologies reported that it received a Nasdaq notice on August 22, 2025 stating that it no longer meets continued listing standards for the Nasdaq Capital Market. The company’s stockholders’ equity was $1,334,000 as of June 30, 2025, below the required $2.5 million, and it also failed alternative criteria based on market value of listed securities and net income from continuing operations. Sonim has 45 days, until October 6, 2025, to submit a plan to regain compliance, and Nasdaq may grant up to 180 days from the notice date to demonstrate compliance if the plan is accepted. The company is evaluating options but warns there is no assurance its plan will be accepted or that it will regain compliance, and its shares could ultimately be delisted, although it would have the right to appeal any delisting determination.
Sonim Technologies entered a receivables factoring agreement under which eligible receivables will be purchased at a 15% discount, providing up to €3,000,000 of financing. The facility carries an interest rate equal to the greater of 4.00% or EURIBOR+3.50%, a late fee of 0.18% for invoices outstanding more than 95 days, a risk surcharge of 0.06% of a preapproved limit, and a non-utilization fee of €70,000 if annual sales to Tradewind are below €15,000. The term is 12 months with automatic annual extension and either party may terminate with three months' notice.
The company also amended prior subscription agreements to lower the Subscription Warrant exercise price to $0.75. Because stockholders did not approve an increase in shares under the 2019 Equity Incentive Plan, the compensation committee approved a Substitute Cash Grant to non-employee directors that is designed to replicate RSUs valued at $60,000; those phantom RSUs vest on a change in control or at the 2026 annual meeting and the cash award is payable at the vesting event.
Sonim Technologies, Inc. filed a current report to note that it has released its latest quarterly financial results. On August 8, 2025, the company issued a press release announcing results for its fiscal quarter ended June 30, 2025. That press release is included as Exhibit 99.1 to this report, allowing investors to review the detailed figures and commentary. The filing is made under the item covering results of operations and financial condition and is primarily an administrative step to formally furnish the earnings release.
Sonim Technologies (NASDAQ:SONM) announced significant developments in its strategic alternatives process through an 8-K filing. The company has entered into a non-binding letter of intent for a potential business combination with a private company operating in high-performance computing and AI data processing infrastructure.
The company is pursuing a dual-track strategy: (1) a business combination with the target company and (2) the sale of substantially all of Sonim's operating assets. Both transactions require definitive agreements and are subject to board and stockholder approvals. The company has also filed proxy materials for its 2025 Annual Meeting.